News | Implantable Cardioverter Defibrillator (ICD) | November 04, 2015

LivaNova Launches Platinum ICD/CRT-D Family

Released simultaneously in both Europe and Japan, devices will protect patients from avoidable replacement surgeries

LivaNova, Platinum, ICD, CRT-D, launch, Europe and Japan

Image courtesy of LivaNova PLC


November 4, 2015 — LivaNova PLC, formerly Sorin Group, launched Platinum, a new range of implantable cardiac defibrillators (ICDs) and cardiac resynchronization therapy devices (CRT-Ds).

Platinum offers superior longevity thanks to technology that ensures extremely low electrical intrinsic consumption. In standard functioning conditions, the service life is projected to last over 14 years for the single-chamber ICD model, over 13 years for the dual-chamber ICD model and over 10 years for CRT-D devices.

More than 60 percent of patients are under 70 years of age at the time of their first implant, and more than one-third will require at least one replacement due to battery depletion. Replacement procedures are associated with twice as many surgical re-interventions as compared to de-novo procedures due to increased rates of complications, such as infections. The mortality rate in patients with an infection reaches 16.9 percent at one year and 27.5 percent at three years.

The longevity of Platinum aims to limit the number of device replacements, minimizing the risks that are inherent in replacement surgeries. That longevity has been achieved without compromising the size of the device: Platinum’s size ranges from 31cc to 33cc, and the ErgoformM design of the can, with its rounded shape and smooth edges, was designed to facilitate the implant procedure and improve patient comfort.

Platinum devices also feature proven therapeutic functions such as the PARAD+ arrhythmia discrimination algorithm; SafeR, a pacing mode which preserves natural heart conduction; and SonR, a hemodynamic sensor which automatically optimizes CRT settings.

For more information: www.livanova.com


Related Content

Feature | EP Lab | By Vijay Kundekar

Arrhythmias can be described as irregular heart rhythms that are brought on by numerous factors, including heart damage ...

Home August 23, 2022
Home
News | EP Lab

May 24, 2022 — Attune Medical, a pioneering medical device company with a technology platform based on temperature ...

Home May 24, 2022
Home
News | EP Lab

May 4, 2022 — CathVision, a medical technology company developing innovative electrophysiology solutions designed to ...

Home May 04, 2022
Home
News | EP Lab

April 27, 2022 – CathVision, a medical technology company developing innovative electrophysiology solutions designed to ...

Home April 27, 2022
Home
News | EP Lab

Royal Philips, a global leader in health technology, announced late-breaking results of a large-scale, real-world ...

Home April 12, 2022
Home
News | EP Lab

January 14, 2022 — Medtronic has entered into a definitive agreement to acquire Affera Inc., a Boston area-based ...

Home January 14, 2022
Home
News | EP Lab

January 13, 2022 — Abbott received U.S. Food and Drug Administration (FDA) clearance for the EnSite X EP System with ...

Home January 13, 2022
Home
News | EP Lab

January 7, 2022 — Khaldoun Tarakji, M.D., M.P.H., associate section head of cardiac electrophysiology at the Heart ...

Home January 07, 2022
Home
News | EP Lab

January 5, 2022 — Stereotaxis announced a recent publication in Frontiers in Cardiovascular Medicine titled “Atrial ...

Home January 05, 2022
Home
Feature | EP Lab

Children’s Hospital Los Angeles cardiologist Michael Silka, M.D., helped to pioneer the development of indications for ...

Home December 07, 2021
Home
Subscribe Now